How will Brexit affect health services in the UK? An updated evaluation.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
02 03 2019
Historique:
received: 06 02 2019
revised: 12 02 2019
accepted: 12 02 2019
pubmed: 2 3 2019
medline: 19 4 2019
entrez: 2 3 2019
Statut: ppublish

Résumé

All forms of Brexit are bad for health, but some are worse than others. This paper builds on our 2017 analysis using the WHO health system building blocks framework to assess the likely effects of Brexit on the National Health Service (NHS) in the UK. We consider four possible scenarios as follows: a No-Deal Brexit under which the UK leaves the EU on March 29, 2019, without any formal agreement on the terms of withdrawal; a Withdrawal Agreement, as negotiated between the UK and EU and awaiting (possible) formal agreement, which provides a transition period until the end of December, 2020; the Northern Ireland Protocol's backstop coming into effect after the end of that period; or the Political Declaration on the Future Relationship between the UK and EU. Our analysis shows that a No-Deal Brexit is substantially worse for the NHS than a future involving the Withdrawal Agreement, which provides certainty and continuity in legal relations while the Political Declaration on the Future Relationship is negotiated and put into legal form. The Northern Ireland backstop has varying effects, with continuity in some areas, such as health products, but no continuity in others. The Political Declaration on the Future Relationship envisages a relationship that is centred around a free-trade agreement, in which wider health-related issues are largely absent. All forms of Brexit, however, involve negative consequences for the UK's leadership and governance of health, in both Europe and globally, with questions about the ability of parliament and other stakeholders to scrutinise and oversee government actions.

Identifiants

pubmed: 30819519
pii: S0140-6736(19)30425-8
doi: 10.1016/S0140-6736(19)30425-8
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

949-958

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Nick Fahy (N)

Department of Primary Health Care Sciences, University of Oxford, Oxford, UK.

Tamara Hervey (T)

School of Law, University of Sheffield, Sheffield, UK.

Scott Greer (S)

School of Public Health, University of Michigan, Ann Arbor, MI, USA.

Holly Jarman (H)

School of Public Health, University of Michigan, Ann Arbor, MI, USA.

David Stuckler (D)

Research Centre Dondena, Bocconi University, Milan, Italy.

Mike Galsworthy (M)

Scientists for EU, London, UK.

Martin McKee (M)

Centre for Global Chronic Conditions, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: martin.mckee@lshtm.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH